These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24533958)

  • 1. Development of exogenous FVIII-specific inhibitor in a mild haemophilia patient with Glu272Lys mutation.
    Yamanouchi J; Hato T; Niiya T; Sato Y; Onishi S; Yasukawa M
    Haemophilia; 2014 Mar; 20(2):e179-82. PubMed ID: 24533958
    [No Abstract]   [Full Text] [Related]  

  • 2. In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene.
    Pashov AD; Calvez T; Gilardin L; Maillère B; Repessé Y; Oldenburg J; Pavlova A; Kaveri SV; Lacroix-Desmazes S
    Haemophilia; 2014 Mar; 20(2):176-84. PubMed ID: 24118514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.
    Franchini M; Girelli D; Olivieri O; Castaman G; Lippi G; Poli G; Salvagno GL; Tagariello G; Giuffrida A; de Gironcoli M; Morfini M; Berntorp E; Gandini G
    Haemophilia; 2006 Jul; 12(4):448-51. PubMed ID: 16834751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitor development in haemophilia A patients with inversion of the intron 22 of the factor VIII gene.
    Tizzano EF; Altisent C; Domènech M; Cornet M; Tusell J; Baiget M
    Thromb Haemost; 1996 Jul; 76(1):125-6. PubMed ID: 8819266
    [No Abstract]   [Full Text] [Related]  

  • 5. Analysis of F8 inversions as risk factors for FVIII inhibitor development in Indian severe haemophilia A patients.
    Pinto P; Ghosh K; Shetty S
    Blood Cells Mol Dis; 2014 Sep; 53(3):161-3. PubMed ID: 24824129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-inversion factor VIII mutations in 80 hemophilia A families including 24 with alloimmune responses.
    Liu ML; Nakaya S; Thompson AR
    Thromb Haemost; 2002 Feb; 87(2):273-6. PubMed ID: 11858487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between factor VIII genotype and inhibitor development in hemophilia A.
    Fakharzadeh SS; Kazazian HH
    Semin Thromb Hemost; 2000; 26(2):167-71. PubMed ID: 10919409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.
    Peerlinck K; Jacquemin MG; Arnout J; Hoylaerts MF; Gilles JG; Lavend'homme R; Johnson KM; Freson K; Scandella D; Saint-Remy JM; Vermylen J
    Blood; 1999 Apr; 93(7):2267-73. PubMed ID: 10090936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy.
    Klintman J; Hillarp A; Berntorp E; Astermark J
    Br J Haematol; 2013 Nov; 163(3):385-92. PubMed ID: 24032553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.
    Spena S; Garagiola I; Cannavò A; Mortarino M; Mannucci PM; Rosendaal FR; Peyvandi F;
    J Thromb Haemost; 2018 Apr; 16(4):778-790. PubMed ID: 29399993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor.
    Iioka F; Shimomura D; Nakamura F; Ohno H; Yada K; Nogami K; Shima M
    Haemophilia; 2014 Nov; 20(6):e402-4. PubMed ID: 25354772
    [No Abstract]   [Full Text] [Related]  

  • 12. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia.
    Wootla B; Mahendra A; Dimitrov JD; Friboulet A; Borel-Derlon A; Rao DN; Uda T; Borg JY; Bayry J; Kaveri SV; Lacroix-Desmazes S
    FEBS Lett; 2009 Aug; 583(15):2565-72. PubMed ID: 19595998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors - genetic and environmental factors.
    Lillicrap D; Fijnvandraat K; Santagostino E
    Haemophilia; 2014 May; 20 Suppl 4():87-93. PubMed ID: 24762282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.
    d'Oiron R; Pipe SW; Jacquemin M
    Haemophilia; 2008 Jul; 14 Suppl 3():138-46. PubMed ID: 18510534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of factor VIII inhibitors in two patients with moderate haemophilia A.
    Paschal RD; Meeks SL; Neff AT
    Haemophilia; 2013 Jan; 19(1):e55-7. PubMed ID: 23171275
    [No Abstract]   [Full Text] [Related]  

  • 16. Factor VIII inhibitors in two families with mild haemophilia A: structural analysis of the mutations.
    Knobe KE; Villoutreix BO; Tengborn LI; Petrini P; Ljung RC
    Haemostasis; 2000; 30(5):268-79. PubMed ID: 11251334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational modelling and inhibitor risk: predicting the future?
    Hart DP
    Haemophilia; 2014 Mar; 20(2):155-7. PubMed ID: 24393500
    [No Abstract]   [Full Text] [Related]  

  • 18. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes.
    Suzuki H; Shima M; Arai M; Kagawa K; Fukutake K; Kamisue S; Nakai H; Morichika S; Tanaka I; Inoue M; Gale K; Tuddenham EG; Yoshioka A
    Thromb Haemost; 1997 May; 77(5):862-7. PubMed ID: 9184393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?
    Franchini M; Lippi G
    Thromb Res; 2016 Dec; 148():96-100. PubMed ID: 27816852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence of inhibitors in hemophilia A and the induction of immune tolerance.
    Briët E; Peters M
    Adv Exp Med Biol; 2001; 489():89-97. PubMed ID: 11554594
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.